GW 2016 Chart
The biopharmaceutical company intends to submit a brand new drug application using the Food and drug administration within the first 1 / 2 of 2017, the organization stated.
GW’s stock has skyrocketed this season, rising greater than 32 percent.
“We feel this result further shows that Epidiolex provides the potential to become a new effective therapy within the concept of treatment-resistant childhood-onset epilepsies,” GW Pharma Chief executive officer Justin Gover stated within the report.
Lennox-Gastaut syndrome affects about one in 50,000 to at least one in 100,000 children, usually ages three to five, based on the U.S. National Library of drugs.
This trial report follows the announcement in March of positive produces a phase three trial of Epidiolex to treat Dravet syndrome, an uncommon type of epilepsy that starts in infancy.
Shares of GW Pharmaceutical drugs leaped greater than 10 % Monday among positive trial recent results for its drug Epidiolex.
Epidiolex was handed orphan status in the U.S. Fda to treat Lennox-Gastaut in 2014 and Dravet syndrome in 2013.
The medication is a therapy option for those who have Lennox-Gastaut syndrome, an uncommon and severe type of childhood-onset epilepsy. Within the trial, when patients added Epidiolex for their current treatment regimen, they found a stop by the regularity of monthly seizures, based on the report.